Clinical Trials Directory

Trials / Completed

CompletedNCT00360269

Atomoxetine Treatment for ADHD and Marijuana Dependence

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
38 (actual)
Sponsor
Medical University of South Carolina · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to determine if atomoxetine treatment combined with motivational enhancement therapy is effective in reducing marijuana use in adult individuals with attention-deficit hyperactivity disorder and marijuana dependence.

Detailed description

The purpose of this study is to determine whether the medication atomoxetine, or Strattera, plus 3 sessions of counseling can help people to reduce the symptoms of ADHD and to help cut back on their marijuana use. Participation in the study is approximately 12 weeks of medication treatment and doctor's visits once a week. The first 2 visits consist of evaluations to determine if you qualify to participate. These visits are approximately 2-3 hours long and will include questions about your past and present substance use, psychiatric history, a routine physical exam, bloodwork, and paper and pencil questionnaires about your marijuana use. Once you are enrolled in the study, visits are typically 30 minutes long, once a week. The one-on-one counseling sessions regarding marijuana use are 1 hour long and you will have 3 sessions throughout the study. If you qualify for this study, you will receive either atomoxetine, or a placebo (sugar pill). Study participants will have a 50% chance of receiving atomoxetine. Atomoxetine is a non-stimulant, commonly used to treat ADHD.

Conditions

Interventions

TypeNameDescription
DRUGAtomoxetine25 to 100 mg daily
PROCEDUREMotivational enhancement therapyThree sessions
DRUGPlacebo25 to 100 mg daily

Timeline

Start date
2005-11-01
Primary completion
2008-06-01
Completion
2008-06-01
First posted
2006-08-04
Last updated
2014-12-30
Results posted
2012-04-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00360269. Inclusion in this directory is not an endorsement.